Managers / Q4 2024 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $66M in U.S.-listed holdings across 15 positions for Q4 2024.
The portfolio is heavily concentrated: ARWR alone accounts for 20.1% of reported value.
Compared with Q3 2024, the fund opened 2 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 87.5% · $58M
- ADR · 8.5% · $6M
- Other · 4.0% · $3M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| AMGNAMGEN INC | NEW | +25.0K | 25.0K | +$7M | $7M |
| PTGXPROTAGONIST THERAPEUTICS INC | NEW | +76.6K | 76.6K | +$3M | $3M |
| SPYSPDR S&P 500 ETF TR | SOLD OUT | −75.0K | 0 | −$43M | $0 |
| MERUS N V | SOLD OUT | −117.9K | 0 | −$6M | $0 |
| SUTRO BIOPHARMA INC | TRIMMED | −762.0K | 498 | −$3M | $916 |
| RGNXREGENXBIO INC | TRIMMED | −584.4K | 346.3K | −$7M | $3M |
| DTILPRECISION BIOSCIENCES INC | ADDED | +154.6K | 536.4K | −$1M | $2M |
| RPTXREPARE THERAPEUTICS INC | ADDED | +304.4K | 1.29M | −$2M | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 20.06% | $13M | 707.6K |
| 2 | BLUEPRINT MEDICINES CORP | COM | 17.04% | $11M | 129.6K |
| 3 | KYMRKYMERA THERAPEUTICS INChistory → | COM | 11.13% | $7M | 183.5K |
| 4 | ARVNARVINAS INChistory → | COM | 9.50% | $6M | 328.8K |
| 5 | BCYCBICYCLE THERAPEUTICS PLChistory → | SPONSORED ADS | 4.68% | $3M | 221.9K |
| 6 | PTGXPROTAGONIST THERAPEUTICS INChistory → | COM | 4.46% | $3M | 76.6K |
| 7 | RGNXREGENXBIO INChistory → | COM | 4.04% | $3M | 346.3K |
| 8 | IMMATICS N.V | SHS | 4.01% | $3M | 373.9K |
| 9 | SLNSILENCE THERAPEUTICS PLChistory → | ADS | 3.81% | $3M | 367.2K |
| 10 | ADICET BIO INC | COM | 3.67% | $2M | 2.53M |
| 11 | DTILPRECISION BIOSCIENCES INChistory → | COM NEW | 3.08% | $2M | 536.4K |
| 12 | RPTXREPARE THERAPEUTICS INChistory → | COM | 2.56% | $2M | 1.29M |
| 13 | SUTRO BIOPHARMA INC | COM | 0.00% | $916 | 498 |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.